Larimar Therapeutics Inc (LRMR)
6.46
0.00 (0.00%)
USD |
NASDAQ |
Apr 24, 16:00
6.46
0.00 (0.00%)
After-Hours: 20:00
Larimar Therapeutics Cash from Financing (TTM): 0.03M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 0.03M |
September 30, 2023 | -0.286M |
June 30, 2023 | 75.26M |
March 31, 2023 | 75.26M |
December 31, 2022 | 75.26M |
September 30, 2022 | 75.57M |
June 30, 2022 | 19.88M |
Date | Value |
---|---|
March 31, 2022 | 19.88M |
December 31, 2021 | 19.88M |
September 30, 2021 | 20.13M |
June 30, 2021 | 0.107M |
March 31, 2021 | 84.01M |
December 31, 2020 | 93.59M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.286M
Minimum
Sep 2023
93.59M
Maximum
Dec 2020
42.97M
Average
20.13M
Median
Sep 2021
Cash from Financing (TTM) Benchmarks
Cogent Biosciences Inc | 163.54M |
ACADIA Pharmaceuticals Inc | 25.13M |
PTC Therapeutics Inc | 646.40M |
Renovaro Inc | 8.766M |
G1 Therapeutics Inc | -26.91M |